Coagulation protein disease
MONDO:0002242Congenital or acquired deficiency of one of the coagulation factors. It results in bleeding.
Also known as: coagulation factor deficiency, coagulation factor deficiency syndrome
277 clinical trials for this condition and its sub-types, 13 tagged with Coagulation protein disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Coagulation protein disease
-
Hemophilia 55 trials · 216 incl. sub-types
4 sub-types
- Hemophilia A 180 trials Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Acquired hemophilia 2 trials · 8 incl. sub-types Sub-types →
- Factor XI deficiency 0 trials Sub-types →
-
Von Willebrand disease (hereditary or acquired) 39 trials · 46 incl. sub-types
2 sub-types
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Acquired von willebrand syndrome 3 trials
-
Acquired coagulation factor deficiency 4 trials · 16 incl. sub-types
6 sub-types
- Acquired hemophilia 2 trials · 8 incl. sub-types Sub-types →
- Acquired von willebrand syndrome 3 trials
- Acquired factor X deficiency 1 trial
- Acquired factor V deficiency 0 trials
- Acquired factor VII deficiency 0 trials
- Acquired factor XIII deficiency 0 trials
-
Factor VII deficiency 6 trials
2 sub-types
- Congenital factor VII deficiency 3 trials
- Acquired factor VII deficiency 0 trials
-
Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types
1 sub-type
- Familial dysfibrinogenemia 2 trials · 6 incl. sub-types Sub-types →
-
Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types
5 sub-types
-
Factor X deficiency 2 trials
2 sub-types
- Acquired factor X deficiency 1 trial
- Congenital factor X deficiency 0 trials
-
Congenital factor XII deficiency 1 trial
-
Hypoplasminogenemia 1 trial
-
East Texas bleeding disorder 0 trials
-
Tatsumi factor deficiency 0 trials
-
Alpha-2-plasmin inhibitor deficiency 0 trials
-
Dysplasminogenemia 0 trials
-
Factor V amsterdam bleeding disorder 0 trials
-
Factor V atlanta bleeding disorder 0 trials
-
Factor V deficiency 0 trials
2 sub-types
- Acquired factor V deficiency 0 trials
- Congenital factor V deficiency 0 trials
-
Factor XIII deficiency 0 trials
2 sub-types
- Acquired factor XIII deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
-
Inherited prekallikrein deficiency 0 trials
-
Plasminogen deficiency, type II 0 trials
Most studied deeper sub-types
-
Can a single gene shot free hemophilia b patients from regular infusions?
Cure Stopped earlyThis trial tests a gene therapy called FLT180a in adults with hemophilia B, a condition where the body lacks a clotting protein. The therapy delivers a working gene to help the body produce its own clotting factor. A small group of participants will receive a single dose and be f…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Can a clotting boost make surgery safer for hemophilia patients?
Disease control Stopped earlyThis trial tests whether a medication called eptacog beta can safely prevent excessive bleeding in people with hemophilia A or B who have inhibitors and need major surgery. Participants receive the drug during and after their operation, and doctors measure how well bleeding is co…
Phase 3 • Sponsor: Laboratoire français de Fractionnement et de Biotechnologies • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Clotting drug may replace plasma transfusions in heart surgery
Disease control Stopped earlyThis study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …
Phase 4 • Sponsor: SHI Jia • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control Stopped earlyThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Phase 1/2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hemophilia drug study falls short: only 3 patients enrolled before termination
Disease control Stopped earlyThis study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control Stopped earlyThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Gene Editing's lasting impact: a 10-Year safety watch
Knowledge-focused Stopped earlyThis study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could home blood tests transform hemophilia care? study seeks patient views
Knowledge-focused Stopped earlyThis study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC